Spondylitis, Ankylosing Clinical Trial
Official title:
Methotrexate in the Treatment of Axial Spondyloarthritis. A Randomized, Multicenter, Double-Blind, Placebo-Controlled Study.
The goal of this study is to evaluate the efficacy of oral methotrexate for the treatment of active axial spondyloarthritis (early ankylosing spondylitis or spondyloarthritis with sacroiliitis). Efficacy will be measured by reduction in the signs and symptoms of active spondyloarthritis including effects on back pain and stiffness, range of motion in the spine, physical function, quality of life and incidence of arthritis, enthesitis and anterior uveitis.
The established classification criteria for ankylosing spondylitis (AS) rely on the
combination of clinical symptoms plus radiographic sacroiliitis of at least grade 2
bilaterally or grade 3 unilaterally. It usually takes several years for definite
radiographic sacroiliitis to evolve. Diagnosis of AS may be delayed up to 10 years after the
onset of symptoms, if diagnosis is based on the radiographic findings.
A group of leading experts in the field of spondyloarthropathies proposed in 2004 the term
"axial spondyloarthritis" as an attempt to narrow the gap of 5-10 years between the first
symptoms and the diagnosis of AS (Rudwaleit et al. Ann Rheum Dis 2004; 63:535-43). Using the
proposed approach, an early diagnosis of AS (or axial spondyloarthritis) can be made with a
high degree of confidence, when at least two to three spondyloarthritis features (clinical
findings, laboratory tests or skeletal imaging) are present. Magnetic resonance imaging
(MRI) of the sacroiliac joints appears to be especially useful tool in the diagnosis of
early AS. Early diagnosis and treatment could probably prevent structural damage and lead to
better functional outcomes.
Treatment of AS has largely consisted of non-steroidal anti-inflammatory drugs (NSAIDs).
Most disease modifying antirheumatic drugs are not effective in axial manifestations.
Sulfasalazine has some efficacy on peripheral symptoms. Tumor necrosis factor (TNF) alpha
blocking drugs infliximab and etanercept are effective in both axial and peripheral
manifestations of the disease. According to consensus statement, the initiation of anti-TNF
alpha therapy requires a definitive diagnosis of AS, which is based on radiographic evidence
of sacroiliitis.
It is well documented, that oral methotrexate is effective and safe in the treatment of
rheumatoid arthritis and psoriatic arthritis. Still, studies proving its usefulness for the
treatment of AS are lacking. To this date, three small randomised and controlled trials to
clarify this issue have been conducted. The dose of methotrexate used in these studies was
low, only 7,5 - 10 mg per week. One of these studies showed a benefit in the active
treatment group. There was no statistically significant benefit of methotrexate in the two
other studies.
The purpose of this study is to assess the efficacy of oral methotrexate in adult subjects
with active axial spondyloarthritis. Subjects will be randomly assigned to placebo or
methotrexate treatment groups. All subjects in the active treatment group receive at least a
dose of 15 mg per week of oral methotrexate. To reduce mucosal, gastrointestinal and
haematologic side effects of low-dose methotrexate all study subjects receive also a dose of
5 mg per week of folic acid. A stable dose of NSAID during the study is permitted. The
duration of the double-blinded treatment period is 24 weeks.
Efficacy of the treatment is measured by reduction in the signs and symptoms of axial
spondyloarthritis at weeks 12 and 24. If the primary outcome of ASAS20 (ASsessment in
Ankylosing Spondylitis response criteria, improvement of at least 20 % in patient reported
symptoms) is not met at the week 12, the dose of methotrexate or corresponding placebo will
be increased to 20 mg per week during weeks 12 to 24.
Clinical history of anterior uveitis and its incidence during the study is also recorded. An
ophthalmologic examination is performed at baseline and week 24.
To a subset of patients a MRI scan of sacroiliac joints will be done also at week 24, to
assess changes of active inflammatory lesions as detected by MRI.
An extension study of radiological progression is also planned. X-ray changes of sacroiliac
joints and lumbosacral spine will be assessed at baseline and at 3 and 5 years.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01208207 -
A Two-Part 26-Week Study of Etoricoxib as Treatment for Ankylosing Spondylitis (AS) (MK-0663-108)
|
Phase 3 | |
Completed |
NCT02509026 -
Etanercept Withdrawal And Retreament Study In Subjects With Nr-ax SpA
|
Phase 4 | |
Completed |
NCT02704845 -
Biopsychosocial Exploration of Pain Profiles in Inflammatory and Chronic Non-specific Axial Low Back Pain
|
N/A | |
Terminated |
NCT01209702 -
A Study of RoActemra/Actemra (Tocilizumab) in Patients With Ankylosing Spondylitis Who Have Failed Treatment With NSAIDs
|
Phase 3 | |
Terminated |
NCT01209689 -
A Study of Tocilizumab (RoActemra/Actemra) in Patients With Ankylosing Spondylitis Who Have Had an Inadequate Response to Previous Tumor Necrosis Factor (TNF) Antagonist Therapy
|
Phase 3 | |
Terminated |
NCT00766402 -
An Efficacy and Safety Study of Tramadol/Acetaminophen Versus Diclofenac in the Treatment of Pain in Participants With Ankylosing Spondylitis Receiving Stable Treatment of Disease Modifying Anti-rheumatic Drugs (DMARDs)
|
Phase 4 | |
Completed |
NCT00000433 -
Blocking Tumor Necrosis Factor in Ankylosing Spondylitis
|
Phase 2 | |
Completed |
NCT00779012 -
A Study of the Efficacy and Tolerance of Remicade in the Treatment of Active Ankylosing Spondylitis (Study P04042)(COMPLETED)
|
Phase 4 | |
Completed |
NCT00779935 -
Growth Factor Concentration to Predict an Ankylosing Spondylitis Patient's Response to Infliximab (Study P04041)(COMPLETED)
|
Phase 4 | |
Completed |
NCT01863732 -
Extension in AS: Sustainability of Benefits, Safety and Tolerability
|
Phase 3 | |
Recruiting |
NCT05879419 -
Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases
|
Phase 4 | |
Completed |
NCT01567878 -
Ultrasound of Enthesis in Patients With Ankylosing Spondylitis: a Comparative Study With Health Subjects
|
N/A | |
Completed |
NCT01188655 -
Observational Non-Interventional Study With Enbrel (Etanercept) in Patients With Ankylosing Spondylitis
|
N/A | |
Completed |
NCT00760669 -
An Observational Study of Infliximab Injection in Ankylosing Spondylitis, Rheumatoid Arthritis, Psoriatic Arthritis and Psoriasis Participants
|
Phase 4 | |
Completed |
NCT02159053 -
16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Ankylosing Spondylitis
|
Phase 3 | |
Completed |
NCT00202865 -
Evaluation of Low Dose Infliximab in Ankylosing Spondylitis (Study P04352)
|
Phase 3 | |
Completed |
NCT02374502 -
Increasing Physical Activity in Ankylosing Spondylitis: a Randomised Controlled Trial
|
N/A | |
Terminated |
NCT00273858 -
Study Evaluating the Safety of Etanercept in Rheumatoid Arthritis, Ankylosing Spondylitis and Psoriatic Arthritis
|
N/A | |
Completed |
NCT04810715 -
Frequency of Pes Planus and Posterior Tibial Tendon Dysfunction in Patients With Ankylosing Spondylitis
|
||
Completed |
NCT03880968 -
Treat-to-Target Strategy With Etanercept for Ankylosing Spondylitis
|